Pathology: breast cancer - adjuvant;
| breast cancer - adjuvant | ||||||
| BCIRG-006 (TCH vs AC-T), 2011 | BCIRG-006 (AC-TH vs TCH), 2011 | BCIRG-006 (AC-TH vs AC-T), 2011 | ExteNET, 2016 | APHINITY, 2017 | ||
| doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab | 2 | T1 | T1 | |||
| pertuzumab plus trastuzumab | 1 | T1 | ||||
| neratinib | 1 | T1 | ||||
| docetaxel plus carboplatin with trastuzumab followed by trastuzumab | 1 | T1 | T0 | |||
| trastuzumab | 0 | T0 | ||||
| placebo | 0 | T0 | ||||
| doxorubicin plus cyclophosphamide followed by docetaxel | 0 | T0 | T0 | |||